A detailed history of General Atlantic LLC transactions in Pharvaris N.V. stock. As of the latest transaction made, General Atlantic LLC holds 7,531,252 shares of PHVS stock, worth $147 Million. This represents 3.99% of its overall portfolio holdings.

Number of Shares
7,531,252
Previous 7,531,252 -0.0%
Holding current value
$147 Million
Previous $142 Million 1.49%
% of portfolio
3.99%
Previous 4.48%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$21.26 - $32.07 $29.2 Million - $44.1 Million
1,375,000 Added 22.34%
7,531,252 $174 Million
Q4 2023

Feb 13, 2024

BUY
$15.2 - $28.05 $26.6 Million - $49.1 Million
1,750,000 Added 39.72%
6,156,252 $173 Million
Q2 2023

Aug 11, 2023

BUY
$7.82 - $16.0 $15.5 Million - $31.8 Million
1,986,097 Added 82.06%
4,406,252 $66.7 Million
Q1 2021

May 17, 2021

BUY
$25.25 - $40.11 $61.1 Million - $97.1 Million
2,420,155 New
2,420,155 $67.7 Million

Others Institutions Holding PHVS

About Pharvaris N.V.


  • Ticker PHVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,766,000
  • Market Cap $658M
  • Description
  • Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...
More about PHVS
Track This Portfolio

Track General Atlantic LLC Portfolio

Follow General Atlantic LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of General Atlantic LLC, based on Form 13F filings with the SEC.

News

Stay updated on General Atlantic LLC with notifications on news.